Jonathan Violin
CIK 1730615 · Chief Executive Officer · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRDN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 200
CHESTERBROOK, PA 19087
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
| DNTH | Director | — | $90.77 | — | $0 | 4 | 2026-05-22 |
| Astria Therapeutics, Inc. (ATXS) Delisted | Director | 0 | $12.58 | $0 | $0 | 7 | 2026-01-23 |
| VRDN | Chief Executive Officer | 480,905 | $30.05 | $14.45M | -$6.11M | 9 | 2023-02-07 |
| Astria Therapeutics, Inc. (CATB) Delisted | Director | — | $8.54 | — | $0 | 2 | 2021-06-02 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | President and COO | 3,342 | — | — | $0 | 1 | 2020-10-30 |
| TREVENA INC (TRVN) Delisted | SVP-Scientific Affairs & IR | — | $0.01 | — | $0 | 1 | 2018-03-02 |
Recent Filings · Page 2 of 3
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-02-07 | VRDN | Mixed | — | -$1.83M | EDGAR |
| 2023-02-03 | VRDN | Sell (S) | −50,000 | -$1.84M | EDGAR |
| 2022-06-21 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-02 | VRDN | Sell (S) | −30,000 | -$366.0K | EDGAR |
| 2022-05-04 | VRDN | Sell (S) | −30,000 | -$391.2K | EDGAR |
| 2022-04-05 | VRDN | Sell (S) | −30,000 | -$567.6K | EDGAR |
| 2022-03-03 | VRDN | Sell (S) | −30,000 | -$529.5K | EDGAR |
| 2022-02-03 | VRDN | Mixed | −30,000 | -$572.8K | EDGAR |
| 2021-12-10 | VRDN | Conv (C) | +627,564 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.